BR112015002709A2 - novos compostos de pirrolopirimidina como inibidores de proteínas quinases - Google Patents

novos compostos de pirrolopirimidina como inibidores de proteínas quinases

Info

Publication number: BR112015002709A2
Authority: BR; Brazil
Prior art keywords: protein kinase; kinase inhibitors; pyrrolopyrimidine compounds; new; new pyrrolopyrimidine
Prior art date: 2012-08-06

Application number

BR112015002709A

Other languages

English (en)

Other versions

BR112015002709B1 (pt

Inventor

Xi Biao

Zhao Li

Mao Long

Xu Xiao

Wang Xiaobo

Original Assignee

Acea Biosciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-08-06

Filing date

2013-07-11

Publication date

2017-07-04

2013-03-15 Priority claimed from US13/843,554 external-priority patent/US9034885B2/en

2013-07-11 Application filed by Acea Biosciences Inc filed Critical Acea Biosciences Inc

2017-07-04 Publication of BR112015002709A2 publication Critical patent/BR112015002709A2/pt

2022-09-20 Publication of BR112015002709B1 publication Critical patent/BR112015002709B1/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Rheumatology (AREA)
Oncology (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Ophthalmology & Optometry (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Epidemiology (AREA)

BR112015002709-1A 2012-08-06 2013-07-11 Compostos, composição farmacêutica, uso dos mesmos e uso de uma combinação de composto ou composição farmacêutica e um segundo agente profilático ou agente terapêutico BR112015002709B1 (pt)

Applications Claiming Priority (9)

Application Number	Priority Date	Filing Date	Title
US201261680231P	2012-08-06	2012-08-06
US61/680,231		2012-08-06
US13/843,554		2013-03-15
US13/843,554 US9034885B2 (en)	2012-01-13	2013-03-15	EGFR modulators and uses thereof
US201361814147P	2013-04-19	2013-04-19
US61/814,147		2013-04-19
US13/917.514		2013-06-13
US13/917,514 US8685988B2 (en)	2012-08-06	2013-06-13	EGFR modulators and uses thereof
PCT/US2013/050163 WO2014025486A1 (en)	2012-08-06	2013-07-11	Novel pyrrolopyrimidine compounds as inhibitors of protein kinases

Publications (2)

Publication Number	Publication Date
BR112015002709A2 true BR112015002709A2 (pt)	2017-07-04
BR112015002709B1 BR112015002709B1 (pt)	2022-09-20

Family

ID=50068479

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR112015002709-1A BR112015002709B1 (pt)	2012-08-06	2013-07-11	Compostos, composição farmacêutica, uso dos mesmos e uso de uma combinação de composto ou composição farmacêutica e um segundo agente profilático ou agente terapêutico

Country Status (23)

Country	Link
EP (2)	EP2880035B9 (pt)
JP (2)	JP6215938B2 (pt)
KR (1)	KR102181365B1 (pt)
CN (2)	CN103748096B (pt)
AU (1)	AU2013300106B2 (pt)
BR (1)	BR112015002709B1 (pt)
CA (1)	CA2881275C (pt)
CY (1)	CY1120844T1 (pt)
DK (1)	DK2880035T3 (pt)
ES (2)	ES2733576T3 (pt)
HK (1)	HK1210471A1 (pt)
HR (1)	HRP20170311T1 (pt)
HU (1)	HUE031955T2 (pt)
IN (1)	IN2015DN00914A (pt)
LT (1)	LT2880035T (pt)
MX (1)	MX361992B (pt)
NZ (1)	NZ629807A (pt)
PT (1)	PT2880035T (pt)
RU (2)	RU2018104702A (pt)
SG (1)	SG11201500872SA (pt)
SM (1)	SMT201700136T1 (pt)
WO (1)	WO2014025486A1 (pt)
ZA (2)	ZA201500762B (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT3409278T (pt)	2011-07-21	2020-12-18	Sumitomo Dainippon Pharma Oncology Inc	Inibidores de proteína cinase heterocíclicos
AU2013207712B2 (en)	2012-01-13	2017-08-31	Acea Biosciences Inc.	Heterocyclic compounds and uses as anticancer agents.
US9034885B2 (en)	2012-01-13	2015-05-19	Acea Biosciences Inc.	EGFR modulators and uses thereof
US9464089B2 (en)	2012-01-13	2016-10-11	Acea Biosciences Inc.	Heterocyclic compounds and uses thereof
TW201441227A (zh)	2013-01-16	2014-11-01	Signal Pharm Llc	經取代吡咯并嘧啶化合物、其組合物及其治療方法
RU2019119893A (ru) *	2013-03-14	2019-08-09	Толеро Фармасьютикалз, Инк.	Ингибиторы jak2 и alk2 и способы их использования
RU2677653C2 (ru) *	2013-07-11	2019-01-18	Ацея Байосайенсиз Инк.	Производные пиримидина в качестве ингибиторов киназы
WO2015127234A1 (en) *	2014-02-20	2015-08-27	Board Of Regents, The University Of Texas System	Use of ibrutinib to treat egfr mutant cancer
EP3169686A4 (en)	2014-07-14	2018-01-24	Signal Pharmaceuticals, LLC	Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
NZ629796A (en)	2014-07-14	2015-12-24	Signal Pharm Llc	Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
EP3778605A3 (en)	2015-02-13	2021-03-10	Dana Farber Cancer Institute, Inc.	Lrrk2 inhibitors and methods of making and using the same
JP2018104290A (ja) *	2015-04-28	2018-07-05	アステラス製薬株式会社	ピラジンカルボキサミド化合物を有効成分とする医薬組成物
WO2016173438A1 (zh) *	2015-04-29	2016-11-03	南京明德新药研发股份有限公司	稠环或三环芳基嘧啶化合物用作激酶抑制剂
WO2017011720A1 (en) *	2015-07-16	2017-01-19	Signal Pharmaceuticals, Llc	Solod forms 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d] oxazol-6-yl)17h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
CA3001744A1 (en) *	2015-10-09	2017-04-13	ACEA Therapeutics, Inc.	Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
CN105646496B (zh) *	2016-01-20	2018-07-20	华侨大学	一种7H-吡咯并[2,3-d]嘧啶衍生物、其合成方法及应用
CN107540661A (zh) *	2016-06-24	2018-01-05	正大天晴药业集团股份有限公司	作为egfr抑制剂的苯胺嘧啶化合物的结晶
CN107663207B (zh) *	2016-07-27	2021-07-30	南京圣和药业股份有限公司	一种egfr激酶抑制剂的甲磺酸盐结晶及制备方法
CN107663208B (zh) *	2016-07-27	2021-10-15	南京圣和药业股份有限公司	一种新型egfr激酶抑制剂的药用盐及其制备方法与用途
CN107955019B (zh) *	2016-10-17	2021-09-14	广东众生药业股份有限公司	一种egfr抑制剂的盐型、晶型及其制备方法
CN106749266B (zh) *	2016-11-14	2019-01-22	山东大学	吡咯并[2,3-d]嘧啶类化合物的高效制备方法
CN108299419B (zh) *	2017-01-11	2022-04-26	南京圣和药业股份有限公司	一种新型egfr激酶抑制剂的几种新晶型及其制备方法
WO2018145525A1 (zh) *	2017-02-08	2018-08-16	中国医药研究开发中心有限公司	吡咯并芳杂环类化合物及其制备方法和医药用途
EP3606925A1 (en) *	2017-04-07	2020-02-12	ACEA Therapeutics, Inc.	Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
CN109422751B (zh) *	2017-09-03	2022-04-22	上海美志医药科技有限公司	一类具有降解酪氨酸蛋白激酶jak3活性的化合物
US11709155B2 (en)	2017-09-18	2023-07-25	Waters Technologies Corporation	Use of vapor deposition coated flow paths for improved chromatography of metal interacting analytes
US12181452B2 (en)	2017-09-18	2024-12-31	Waters Technologies Corporation	Use of vapor deposition coated flow paths for improved chromatography of metal interacting analytes
US11709156B2 (en)	2017-09-18	2023-07-25	Waters Technologies Corporation	Use of vapor deposition coated flow paths for improved analytical analysis
US12180581B2 (en)	2017-09-18	2024-12-31	Waters Technologies Corporation	Use of vapor deposition coated flow paths for improved chromatography of metal interacting analytes
HRP20221043T1 (hr) *	2017-12-28	2022-11-11	Daewoong Pharmaceutical Co., Ltd.	Derivat oksi-fluoropiperidina kao inhibitor kinaze
KR102577241B1 (ko)	2017-12-28	2023-09-11	주식회사 대웅제약	카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체
KR102577242B1 (ko)	2017-12-28	2023-09-11	주식회사 대웅제약	카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
US11013741B1 (en)	2018-04-05	2021-05-25	Sumitomo Dainippon Pharma Oncology, Inc.	AXL kinase inhibitors and use of the same
EP3773560A4 (en)	2018-04-13	2022-01-19	Sumitomo Dainippon Pharma Oncology, Inc.	PIM KINASE INHIBITORS FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS AND CANCER-ASSOCIATED FIBROSIS
CN108530450B (zh) *	2018-05-03	2021-03-30	赖建智	具有egfr抑制活性的化合物、制备方法及其在疾病治疗中的应用
CA3103995A1 (en)	2018-07-26	2020-01-30	Sumitomo Dainippon Pharma Oncology, Inc.	Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
EP3613738A1 (en) *	2018-08-23	2020-02-26	Lead Discovery Center GmbH	4-substituted pyrrolo[2,3-b]pyridine as erbb modulators useful for treating cancer
CA3127502A1 (en)	2019-02-12	2020-08-20	Sumitomo Dainippon Pharma Oncology, Inc.	Formulations comprising heterocyclic protein kinase inhibitors
CN111747950B (zh) *	2019-03-29	2024-01-23	深圳福沃药业有限公司	用于治疗癌症的嘧啶衍生物
CN110407840A (zh) *	2019-08-15	2019-11-05	重庆化工职业学院	一种艾维替尼的制备方法
WO2021093839A1 (zh) *	2019-11-13	2021-05-20	南京明德新药研发有限公司	作为btk抑制剂的吡咯并嘧啶类化合物及其应用
US11918936B2 (en)	2020-01-17	2024-03-05	Waters Technologies Corporation	Performance and dynamic range for oligonucleotide bioanalysis through reduction of non specific binding
CN115023428A (zh) *	2020-01-21	2022-09-06	江苏先声药业有限公司	嘧啶并吡咯类化合物
CN111848631B (zh) *	2020-08-28	2022-04-19	四川大学华西医院	一种靶向EGFR突变的吡咯并[2,3-d]嘧啶衍生物及其制备方法和用途
US20240100172A1 (en)	2020-12-21	2024-03-28	Hangzhou Jijing Pharmaceutical Technology Limited	Methods and compounds for targeted autophagy
CN115087641B (zh)	2021-01-11	2024-06-18	广州力鑫生物科技有限公司	2-氨基嘧啶类化合物及其药物组合物和应用
CN114957248B (zh) *	2022-05-09	2023-12-29	南开大学	一种吡咯并嘧啶化合物及其制备方法、药物组合物和应用
CN115611989B (zh) *	2022-10-09	2023-08-01	武汉理工大学	机械活化淀粉衍生物抑制剂的优化制备方法及应用
WO2024092047A1 (en)	2022-10-26	2024-05-02	Sorrento Therapeutics, Inc.	Administration of pyrrolopyrimidine-based kinase inhibitors for treatment of psoriasis
WO2024097653A1 (en)	2022-10-31	2024-05-10	Sumitomo Pharma America, Inc.	Pim1 inhibitor for treating myeloproliferative neoplasms

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5563905A (en)	1992-09-24	1996-10-08	Hughes Aircraft Company	Network communication system having time-sliced protocol
US7560269B2 (en)	2002-12-20	2009-07-14	Acea Biosciences, Inc.	Real time electronic cell sensing system and applications for cytotoxicity profiling and compound assays
US7468255B2 (en)	2002-12-20	2008-12-23	Acea Biosciences	Method for assaying for natural killer, cytotoxic T-lymphocyte and neutrophil-mediated killing of target cells using real-time microelectronic cell sensing technology
ATE448482T1 (de)	2002-07-20	2009-11-15	Acea Biosciences Inc	Vorrichtungen auf impedanzbasis sowie verfahren zur verwendung in assays
US7470533B2 (en)	2002-12-20	2008-12-30	Acea Biosciences	Impedance based devices and methods for use in assays
US7732127B2 (en)	2002-12-20	2010-06-08	Acea Biosciences, Inc.	Dynamic monitoring of cell adhesion and spreading using the RT-CES system
CA2550274A1 (en)	2003-11-12	2005-05-26	Acea Biosciences, Inc.	Real time electronic cell sensing systems and applications for cell-based assays
EP1928872B1 (en) *	2005-09-21	2012-03-14	4Sc Ag	Novel sulphonylpyrroles as inhibitors of hdac
KR101705158B1 (ko) *	2009-05-05	2017-02-09	다나-파버 캔서 인스티튜트 인크.	Ｅｇｆｒ 억제제 및 질환 치료방법
US20110207736A1 (en) *	2009-12-23	2011-08-25	Gatekeeper Pharmaceuticals, Inc.	Compounds that modulate egfr activity and methods for treating or preventing conditions therewith

2013
- 2013-07-11 KR KR1020157006007A patent/KR102181365B1/ko active IP Right Grant
- 2013-07-11 JP JP2015526540A patent/JP6215938B2/ja active Active
- 2013-07-11 EP EP13745491.4A patent/EP2880035B9/en active Active
- 2013-07-11 BR BR112015002709-1A patent/BR112015002709B1/pt active IP Right Grant
- 2013-07-11 ES ES16202341T patent/ES2733576T3/es active Active
- 2013-07-11 IN IN914DEN2015 patent/IN2015DN00914A/en unknown
- 2013-07-11 SM SM20170136T patent/SMT201700136T1/it unknown
- 2013-07-11 SG SG11201500872SA patent/SG11201500872SA/en unknown
- 2013-07-11 NZ NZ629807A patent/NZ629807A/en not_active IP Right Cessation
- 2013-07-11 MX MX2015001715A patent/MX361992B/es active IP Right Grant
- 2013-07-11 CA CA2881275A patent/CA2881275C/en active Active
- 2013-07-11 WO PCT/US2013/050163 patent/WO2014025486A1/en active Application Filing
- 2013-07-11 RU RU2018104702A patent/RU2018104702A/ru not_active Application Discontinuation
- 2013-07-11 LT LTEP13745491.4T patent/LT2880035T/lt unknown
- 2013-07-11 EP EP16202341.0A patent/EP3170825B1/en active Active
- 2013-07-11 PT PT137454914T patent/PT2880035T/pt unknown
- 2013-07-11 HU HUE13745491A patent/HUE031955T2/en unknown
- 2013-07-11 AU AU2013300106A patent/AU2013300106B2/en active Active
- 2013-07-11 ES ES13745491.4T patent/ES2618007T3/es active Active
- 2013-07-11 DK DK13745491.4T patent/DK2880035T3/en active
- 2013-07-11 CN CN201380001359.4A patent/CN103748096B/zh active Active
- 2013-07-11 CN CN201710229308.7A patent/CN107266453B/zh active Active
- 2013-07-11 RU RU2015107831A patent/RU2645672C2/ru active
2015
- 2015-02-02 ZA ZA2015/00762A patent/ZA201500762B/en unknown
- 2015-11-16 HK HK15111282.7A patent/HK1210471A1/xx unknown
2016
- 2016-01-29 ZA ZA2016/00648A patent/ZA201600648B/en unknown
2017
- 2017-01-17 JP JP2017005935A patent/JP2017061581A/ja not_active Withdrawn
- 2017-02-23 HR HRP20170311TT patent/HRP20170311T1/hr unknown
- 2017-03-02 CY CY171100274T patent/CY1120844T1/el unknown

Also Published As

Publication number	Publication date
DK2880035T3 (en)	2017-03-06
MX361992B (es)	2018-12-19
EP2880035B1 (en)	2016-12-07
HUE031955T2 (en)	2017-08-28
CA2881275C (en)	2020-10-20
CN103748096A (zh)	2014-04-23
AU2013300106A1 (en)	2015-02-19
EP3170825B1 (en)	2019-04-10
JP6215938B2 (ja)	2017-10-18
BR112015002709B1 (pt)	2022-09-20
ZA201600648B (en)	2021-09-29
RU2015107831A (ru)	2016-09-27
SMT201700136T1 (it)	2017-05-08
WO2014025486A1 (en)	2014-02-13
AU2013300106B2 (en)	2017-11-30
MX2015001715A (es)	2015-07-06
JP2017061581A (ja)	2017-03-30
ES2733576T3 (es)	2019-12-02
EP2880035A1 (en)	2015-06-10
KR102181365B1 (ko)	2020-11-23
CN107266453B (zh)	2020-02-07
HRP20170311T1 (hr)	2017-04-21
ES2618007T3 (es)	2017-06-20
EP2880035B9 (en)	2017-05-17
SG11201500872SA (en)	2015-03-30
JP2015524468A (ja)	2015-08-24
CN107266453A (zh)	2017-10-20
CN103748096B (zh)	2017-10-20
HK1210471A1 (en)	2016-04-22
PT2880035T (pt)	2017-03-10
KR20150068949A (ko)	2015-06-22
RU2645672C2 (ru)	2018-02-27
CA2881275A1 (en)	2014-02-13
IN2015DN00914A (pt)	2015-06-12
ZA201500762B (en)	2021-09-29
NZ629807A (en)	2017-04-28
EP3170825A1 (en)	2017-05-24
LT2880035T (lt)	2017-03-27
RU2018104702A (ru)	2019-02-22
CY1120844T1 (el)	2019-12-11

Publication	Publication Date	Title
BR112015002709A2 (pt)	2017-07-04	novos compostos de pirrolopirimidina como inibidores de proteínas quinases
HK1215253A1 (zh)	2016-08-19	作為激酶抑制劑的吡咯並嘧啶化合物
LT3181567T (lt)	2019-07-25	Pirazolpirimidino junginiai kaip kinazės slopikliai
PT2705029T (pt)	2019-02-01	Novos compostos como moduladores de proteína quinases
CO6831983A2 (es)	2014-01-10	Compuestos heterocíclicos como inhibidores de cinasas
CO6950481A2 (es)	2014-05-20	Inhibidores de proteínas quinasas
PT3459942T (pt)	2021-03-26	Inibidores de adn-pk
HK1215577A1 (zh)	2016-09-02	蛋白激酶抑制劑
CO6880068A2 (es)	2014-02-28	Aminoquinazolinas como inhibidores de quinasa
CO6970602A2 (es)	2014-06-13	Inhibidores de quinasa
EP2710007A4 (en)	2015-04-01	Kinase inhibitors
DK2914965T3 (da)	2021-04-26	Aflukker til biologiske mikroobjekter
CO7010838A2 (es)	2014-07-31	Compuestos de imidazopirrolidinona
BR112015003218A2 (pt)	2019-09-24	pirazolil-ureias como inibidores de cinase
IL238693A0 (en)	2015-06-30	Substituted tricyclic benzimidazoles as kinase inhibitors
EP2734205A4 (en)	2014-12-10	HETEROCYCLIC PROTEIN KINASE HEMMER
EP2917210A4 (en)	2016-05-25	KINASE INHIBITORS
IL228311A0 (en)	2013-11-25	Protein kinase inhibitors
CO6862145A2 (es)	2014-02-10	Imidazopiridazinas como inhibidores de quinasa akt
HK1209726A1 (en)	2016-04-08	Protein kinase inhibitors
HK1205506A1 (en)	2015-12-18	Protein kinase inhibitors
CO6990735A2 (es)	2014-07-10	Inhibidores de pirazina cinasa
BR112015005361A2 (pt)	2017-07-04	inibidores de tirosina quinase de bruton
BR112014001977A2 (pt)	2017-02-21	inibidores seletivos de proteína quinase
HK1208460A1 (en)	2016-03-04	Protein kinase inhibitors

Legal Events

Date	Code	Title	Description
2018-01-23	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2019-07-30	B15I	Others concerning applications: loss of priority	Free format text: PERDA DA PRIORIDADE US 61/680,231 REIVINDICADA NO PCT/US2013/050163 CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 7O E ART 2O DA RESOLUCAO INPI 179 DE 21/02/2017. ESTA PERDA SE DEU PELO FATO DE O DEPOSITANTE CONSTANTE DA PETICAO DE REQUERIMENTO DO PEDIDO PCT (ACEA BIOSCIENCES INC.) SER DISTINTO DAQUELES QUE DEPOSITARAM A PRIORIDADE REIVINDICADA E NAO APRESENTOU DOCUMENTO COMPROBATORIO DE CESSAO DENTRO DO PRAZO DE 60 DIAS A CONTAR DA DATA DA ENTRADA DA FASE NACIONAL, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 6O, E NO ART. 28 DA RESOLUCAO INPI-PR 77/2013.
2019-10-15	B12F	Other appeals [chapter 12.6 patent gazette]
2021-03-02	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2021-05-25	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2021-06-01	B06I	Publication of requirement cancelled [chapter 6.9 patent gazette]	Free format text: ANULADA A PUBLICACAO CODIGO 6.21 NA RPI NO 2629 DE 25/05/2021 POR TER SIDO INDEVIDA.
2022-01-04	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2022-07-05	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2022-09-20	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/07/2013, OBSERVADAS AS CONDICOES LEGAIS